1051 related articles for article (PubMed ID: 15617852)
1. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
2. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
Yamagishi S; Takenaka K; Inoue H
Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710
[TBL] [Abstract][Full Text] [Related]
3. New treatment strategies for patients with hypertension and insulin resistance.
Kurtz TW
Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
[TBL] [Abstract][Full Text] [Related]
4. Telmisartan, its potential therapeutic implications in cardiometabolic disorders.
Yamagishi S; Nakamura K
Recent Pat Cardiovasc Drug Discov; 2006 Jan; 1(1):79-83. PubMed ID: 18221077
[TBL] [Abstract][Full Text] [Related]
5. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders.
Yamagishi S; Nakamura K; Matsui T
Curr Mol Med; 2007 Aug; 7(5):463-9. PubMed ID: 17691961
[TBL] [Abstract][Full Text] [Related]
6. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator.
Kurtz TW
Acta Diabetol; 2005 Apr; 42 Suppl 1():S9-16. PubMed ID: 15868121
[TBL] [Abstract][Full Text] [Related]
7. Possible molecular mechanisms by which angiotensin II type 1 receptor blockers (ARBs) prevent the development of atrial fibrillation in insulin resistant patients.
Yamagishi SI; Matsui T; Nakamura K
Horm Metab Res; 2008 Sep; 40(9):640-4. PubMed ID: 18792876
[TBL] [Abstract][Full Text] [Related]
8. Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation.
Younis F; Stern N; Limor R; Oron Y; Zangen S; Rosenthal T
Metabolism; 2010 Aug; 59(8):1200-9. PubMed ID: 20070992
[TBL] [Abstract][Full Text] [Related]
9. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity.
Toyama K; Nakamura T; Kataoka K; Yasuda O; Fukuda M; Tokutomi Y; Dong YF; Ogawa H; Kim-Mitsuyama S
Biochem Biophys Res Commun; 2011 Jul; 410(3):508-13. PubMed ID: 21679694
[TBL] [Abstract][Full Text] [Related]
10. Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE).
Mori Y; Tanaka T; Matsuura K; Yokoyama J; Utsunomiya K
Adv Ther; 2011 Aug; 28(8):698-706. PubMed ID: 21744143
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
12. Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan.
Volpe M
Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):1061-72. PubMed ID: 23030295
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic treatment with telmisartan induces tissue-specific gene modulation favoring normal glucose homeostasis in Cohen-Rosenthal diabetic hypertensive rats.
Younis F; Oron Y; Limor R; Stern N; Rosenthal T
Metabolism; 2012 Feb; 61(2):164-74. PubMed ID: 21820685
[TBL] [Abstract][Full Text] [Related]
14. The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients.
Negro R; Hassan H
J Renin Angiotensin Aldosterone Syst; 2006 Dec; 7(4):243-6. PubMed ID: 17318795
[TBL] [Abstract][Full Text] [Related]
15. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
16. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan.
Ucciferri C; Falasca K; Mancino P; Di Iorio A; Vecchiet J
Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):491-8. PubMed ID: 22696876
[TBL] [Abstract][Full Text] [Related]
17. Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers.
Kintscher U; Unger T
Acta Diabetol; 2005 Apr; 42 Suppl 1():S26-32. PubMed ID: 15868116
[TBL] [Abstract][Full Text] [Related]
18. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
19. Telmisartan: just an antihypertensive agent? A literature review.
Destro M; Cagnoni F; Dognini GP; Galimberti V; Taietti C; Cavalleri C; Galli E
Expert Opin Pharmacother; 2011 Dec; 12(17):2719-35. PubMed ID: 22077832
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.
Benndorf RA; Rudolph T; Appel D; Schwedhelm E; Maas R; Schulze F; Silberhorn E; Böger RH
Metabolism; 2006 Sep; 55(9):1159-64. PubMed ID: 16919533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
